目的探讨急性生理与慢性健康评估(APACHE)Ⅱ和肺损伤预测评分(LIPS)在急性呼吸窘迫综合征(ARDS)病情评估及预后判断中的价值。方法108例ARDS患者根据氧合指数分为轻(n=43)、中(n=35)、重度(n=30)3组,比较各组入院时基本资料。按照治疗2...目的探讨急性生理与慢性健康评估(APACHE)Ⅱ和肺损伤预测评分(LIPS)在急性呼吸窘迫综合征(ARDS)病情评估及预后判断中的价值。方法108例ARDS患者根据氧合指数分为轻(n=43)、中(n=35)、重度(n=30)3组,比较各组入院时基本资料。按照治疗28 d后的预后转归再分为死亡组(n=41)和存活组(n=67),比较两组治疗1、3 d的APACHEⅡ与LIPS变化及与病情的关系,应用受试者工作特征(ROC)曲线评估不同时间点APACHEⅡ和LIPS评估预后的价值。结果入院时轻、中、重度组APACHEⅡ和LIPS差异有统计学意义(P<0.01);存活组和死亡组APACHEⅡ评分均显著升高(P<0.001),且死亡组显著高于存活组(P<0.01);存活组LIPS显著降低(P<0.01),而死亡组LIPS显著升高(P<0.01),两组不同时间点差异均有统计学意义(P<0.01);Pearson相关性分析显示,治疗1、3 d APACHEⅡ和LIPS与病情呈正相关(P<0.05,P<0.001);受试者工作特征(ROC)曲线分析显示,治疗1 d LIPS曲线下面积大于APACHEⅡ评分,但差异无统计学意义(Z=0.929,P=0.353);治疗1 d的LIPS曲线下面积、灵敏度、特异度均显著高于APACHEⅡ评分(Z=2.605,P=0.009)。结论APACHEⅡ和LIPS在ARDS病情评估及预后判断中均具有一定价值,治疗3 d的LIPS预测价值较高,在临床评估病情及判断预后并给予综合治疗中具有指导意义。展开更多
Objective:To explore the aesthetic characteristics of the Chinese children lips.Methods: Frontal and profile photographs of 653 healthy children were categorized as the attractive and the unattractive by three laypers...Objective:To explore the aesthetic characteristics of the Chinese children lips.Methods: Frontal and profile photographs of 653 healthy children were categorized as the attractive and the unattractive by three laypersons and objectively measured for comparison.Results: The attractive group tended to be smaller in the upper paramedian red lip height,the lower paramedian red lip height,the midline upper red lip height,the central bow angle,and the lip angle,while greater in the Cupid’s bow width.Conclusions:Thinner lips seemed to be more attractive than full ones among Chinese children.展开更多
Aims: To investigate the effect on risk of major adverse cardiac events(MACE) of lipid lowering treatment with fluvastatin 80 mg/day after a first percutaneous coronary intervention in patientswith stable and unstable...Aims: To investigate the effect on risk of major adverse cardiac events(MACE) of lipid lowering treatment with fluvastatin 80 mg/day after a first percutaneous coronary intervention in patientswith stable and unstable angina. Method and results: This prespecified subgroup analysis of the LIPS(Lescol intervention prevention study) analysed 1658 patients with documented diagnosis; 824 had unstable angina(417 randomly assigned to fluvastatin, 407 to placebo) and 834 had stable angina(including silent ischaemia; fluvastatin, 418; placebo, 416). Median follow up was 3.9 years. There was no significant effect of anginal status on long term risk of MACE. Fluvastatin treatment reduced the risk ofMACE by 28%compared with placebo (p=0.03) among patients with unstable angina, with no difference between patients with stable and patients with unstable angina(relative risk 1.07, 95%confidence interval 0.87 to 1.30, p=0.53). Fluvastatin reduced coronary atherosclerotic events (MACE excluding restenosis) by 36%(p=0.006) among patients with unstable angina and 31%(p=0.02) among patients with stable angina. Fluvastatin caused similar reductions in total cholesterol and low density lipoprotein cholesterol concentrations in both patient groups. Conclusion: Treatment with fluvastatin 80 mg/day produced significant reductions inMACE and coronary atherosclerotic events after percutaneous coronary intervention in patientswith average cholesterol concentrations. The beneficial effects of fluvastatin are observed in patients with unstable or stable angina alike.展开更多
The iconic image of a giant radiating dyke swarm subsequently fragmented into three pieces via supercontinental breakup was produced by Paul May in1971(see next page).That figure presented a large part of
We consider complex-valued functions f ∈ L^1 （R^2＋）, where R＋ ：= [0,∞）, and prove sufficient conditions under which the double sine Fourier transform fss and the double cosine Fourier transform fcc belong to o...We consider complex-valued functions f ∈ L^1 （R^2＋）, where R＋ ：= [0,∞）, and prove sufficient conditions under which the double sine Fourier transform fss and the double cosine Fourier transform fcc belong to one of the two-dimensional Lipschitz classes Lip（a,β） for some 0 〈 α,β ≤ 1; or to one of the Zygmund classes Zyg（α,β） for some 0 〈 α,β ≤ 2. These sufficient conditions are best possible in the sense that they are also necessary for nonnegative-valued functions f ∈ L^1 （R^2＋）.展开更多
Study objective: To establish the safety and efficacy of small-gel particle hyaluronic acid (SGP-HA;Restylane?, Medicis Aesthetics Inc., Scottsdale, AZ) for lip augmentation. Study design: This was a Phase 3, prospect...Study objective: To establish the safety and efficacy of small-gel particle hyaluronic acid (SGP-HA;Restylane?, Medicis Aesthetics Inc., Scottsdale, AZ) for lip augmentation. Study design: This was a Phase 3, prospective, open-label, evaluator-blinded, single-center pilot study of SGP-HA use in lip augmentation. The primary efficacy objectives were to investigate the efficacy of SGP-HA in lip augmentation and to assess subject satisfaction with the procedure 12 weeks after treatment. Secondary efficacy objectives were to validate 3D imaging to measure lip augmentation, identify subject satisfaction at all points in time, and identify the duration of lip augmentation and palpability of SGP-HA in the lips. The primary safety objective was to assess the incidence, duration, and severity of all adverse experiences. Results: All 20 subjects and the treating investigator indicated improvement in the appearance of subjects’ lips at weeks 2, 6, and 12. SGP-HA administered for augmentation was well tolerated. Four (20%) subjects treated with SGP-HA experienced 7 treatment-emergent adverse events (TEAEs). Conclusions: Results of this study show promising efficacy and an absence of safety issues with the use of SGP-HA in lip augmentation.展开更多
文摘目的探讨急性生理与慢性健康评估(APACHE)Ⅱ和肺损伤预测评分(LIPS)在急性呼吸窘迫综合征(ARDS)病情评估及预后判断中的价值。方法108例ARDS患者根据氧合指数分为轻(n=43)、中(n=35)、重度(n=30)3组,比较各组入院时基本资料。按照治疗28 d后的预后转归再分为死亡组(n=41)和存活组(n=67),比较两组治疗1、3 d的APACHEⅡ与LIPS变化及与病情的关系,应用受试者工作特征(ROC)曲线评估不同时间点APACHEⅡ和LIPS评估预后的价值。结果入院时轻、中、重度组APACHEⅡ和LIPS差异有统计学意义(P<0.01);存活组和死亡组APACHEⅡ评分均显著升高(P<0.001),且死亡组显著高于存活组(P<0.01);存活组LIPS显著降低(P<0.01),而死亡组LIPS显著升高(P<0.01),两组不同时间点差异均有统计学意义(P<0.01);Pearson相关性分析显示,治疗1、3 d APACHEⅡ和LIPS与病情呈正相关(P<0.05,P<0.001);受试者工作特征(ROC)曲线分析显示,治疗1 d LIPS曲线下面积大于APACHEⅡ评分,但差异无统计学意义(Z=0.929,P=0.353);治疗1 d的LIPS曲线下面积、灵敏度、特异度均显著高于APACHEⅡ评分(Z=2.605,P=0.009)。结论APACHEⅡ和LIPS在ARDS病情评估及预后判断中均具有一定价值,治疗3 d的LIPS预测价值较高,在临床评估病情及判断预后并给予综合治疗中具有指导意义。
文摘Objective:To explore the aesthetic characteristics of the Chinese children lips.Methods: Frontal and profile photographs of 653 healthy children were categorized as the attractive and the unattractive by three laypersons and objectively measured for comparison.Results: The attractive group tended to be smaller in the upper paramedian red lip height,the lower paramedian red lip height,the midline upper red lip height,the central bow angle,and the lip angle,while greater in the Cupid’s bow width.Conclusions:Thinner lips seemed to be more attractive than full ones among Chinese children.
文摘Aims: To investigate the effect on risk of major adverse cardiac events(MACE) of lipid lowering treatment with fluvastatin 80 mg/day after a first percutaneous coronary intervention in patientswith stable and unstable angina. Method and results: This prespecified subgroup analysis of the LIPS(Lescol intervention prevention study) analysed 1658 patients with documented diagnosis; 824 had unstable angina(417 randomly assigned to fluvastatin, 407 to placebo) and 834 had stable angina(including silent ischaemia; fluvastatin, 418; placebo, 416). Median follow up was 3.9 years. There was no significant effect of anginal status on long term risk of MACE. Fluvastatin treatment reduced the risk ofMACE by 28%compared with placebo (p=0.03) among patients with unstable angina, with no difference between patients with stable and patients with unstable angina(relative risk 1.07, 95%confidence interval 0.87 to 1.30, p=0.53). Fluvastatin reduced coronary atherosclerotic events (MACE excluding restenosis) by 36%(p=0.006) among patients with unstable angina and 31%(p=0.02) among patients with stable angina. Fluvastatin caused similar reductions in total cholesterol and low density lipoprotein cholesterol concentrations in both patient groups. Conclusion: Treatment with fluvastatin 80 mg/day produced significant reductions inMACE and coronary atherosclerotic events after percutaneous coronary intervention in patientswith average cholesterol concentrations. The beneficial effects of fluvastatin are observed in patients with unstable or stable angina alike.
文摘The iconic image of a giant radiating dyke swarm subsequently fragmented into three pieces via supercontinental breakup was produced by Paul May in1971(see next page).That figure presented a large part of
基金Supported partially by the Program TMOP-4.2.2/08/1/2008-0008 of the Hungarian National Development Agency
文摘We consider complex-valued functions f ∈ L^1 （R^2＋）, where R＋ ：= [0,∞）, and prove sufficient conditions under which the double sine Fourier transform fss and the double cosine Fourier transform fcc belong to one of the two-dimensional Lipschitz classes Lip（a,β） for some 0 〈 α,β ≤ 1; or to one of the Zygmund classes Zyg（α,β） for some 0 〈 α,β ≤ 2. These sufficient conditions are best possible in the sense that they are also necessary for nonnegative-valued functions f ∈ L^1 （R^2＋）.
文摘Study objective: To establish the safety and efficacy of small-gel particle hyaluronic acid (SGP-HA;Restylane?, Medicis Aesthetics Inc., Scottsdale, AZ) for lip augmentation. Study design: This was a Phase 3, prospective, open-label, evaluator-blinded, single-center pilot study of SGP-HA use in lip augmentation. The primary efficacy objectives were to investigate the efficacy of SGP-HA in lip augmentation and to assess subject satisfaction with the procedure 12 weeks after treatment. Secondary efficacy objectives were to validate 3D imaging to measure lip augmentation, identify subject satisfaction at all points in time, and identify the duration of lip augmentation and palpability of SGP-HA in the lips. The primary safety objective was to assess the incidence, duration, and severity of all adverse experiences. Results: All 20 subjects and the treating investigator indicated improvement in the appearance of subjects’ lips at weeks 2, 6, and 12. SGP-HA administered for augmentation was well tolerated. Four (20%) subjects treated with SGP-HA experienced 7 treatment-emergent adverse events (TEAEs). Conclusions: Results of this study show promising efficacy and an absence of safety issues with the use of SGP-HA in lip augmentation.
